The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults

Not Applicable

Completed

Brief Summary: The aim is to analyse the results of per oral immunotherapy treatment in severe milk, peanut or egg allergy in adults. This is the second part of the oral immunotherapy study in adults at Skin and Allergy Hospital. The diagnosis of food allergy is verified with positive history, skin prick tests, egg and milk allergen specific IgE (immunoglobulin E) antibodies. In addition, food allergy is verified with an open label (milk allergy) or blind (peanut and egg allergy) allergen specific challenge test. OIT (oral immunotherapy) is performed according to a detailed plan. Lung function parameters are followed before OIT and and a year after OIT.

Detailed Description: 30 patients with milk allergy (at least 18 year olds), 30 patients with peanut allergy and 30 patients with egg allergy are treated with OIT. The diagnosis of food allergy is verified with positive history, skin prick test, egg and milk allergen specific IgE antibodies. In addition, food allergy is verified with an open label (milk allergy) or blind (peanut and egg allergy) allergen specific challenge test. Quality of life, anxiety and patient history data is collected by questionnaires. All the patients undergo a spirometry with a bronchodilatator test, exhaled nitric oxide test and a methacholine challenge before and a year after oral immunotherapy. All the patients undergoing oral immunotherapy are prescribed with emergency medication such as antihistamine tablets, prednisolon tablets (40mg for three days in adults), epinephrine autoinjector (300 µg per dose) and salbutamol or terbutaline inhalator.

Recruitment & Eligibility

Inclusion Criteria

severe milk, peanut or egg allergy verified with positive symptom history, skin prick tests and serum IgE tests and a challenge test

Exclusion Criteria

instable cerebrovascular or heart disease, active autoimmune disease or cancer, or current use of betablockers.
poorly controlled asthma or FEV1 < 70% (FEV1< -2SD)

Arm && Interventions

Group	Intervention	Description
Peanut allergy	Oral immunotherapy	Peanut oral immunotherapy intervention for peanut allergy
Egg allergy	Oral immunotherapy	Egg oral immunotherapy intervention for egg allergy
Milk allergy	Oral immunotherapy	Milk oral immunotherapy intervention for milk allergy

Primary Outcome Measures

Name	Time	Method
Desensitisation	1 year, through study completion	Increase in tolerated dose (that is no symptoms if accidental exposure) of food compared to the pre-OIT, number of participants

Secondary Outcome Measures

Name	Time	Method
Worries Associated With Food Allergy	1 year, through study completion	Quality of life and reported concerns and worries associated with food allergy using a VAS scale (visual analogue scale) from 0 (no worries) to 100 mm (maximal worries) before OIT and at one year after OIT